STOCK TITAN

Date and Time Announced for First Wave BioPharma CEO James Sapirstein’s Presentation at the 2023 BIO Investor Forum

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
First Wave BioPharma to present at 2023 BIO Investor Forum
Positive
  • First Wave BioPharma will present their business and clinical development strategy at the 2023 BIO Investor Forum.
Negative
  • None.

BOCA RATON, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that Chairman, President, and CEO of First Wave BioPharma James Sapirstein’s presentation at the 2023 BIO Investor Forum will take place at 11:15 a.m. PDT on October 17, 2023 in the Franciscan B Room at the Hilton San Francisco.

In addition to the presentation, members of the First Wave BioPharma management team will conduct one-on-one meetings with registered investors at the conference, showcasing the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.

Details of the presentation are as follows:

Event:2023 BIO Investor Forum
Presentation:First Wave BioPharma Company Overview and Updates - Chairman, President, and CEO James Sapirstein
Date/Time:Tuesday, October 17, 2023; 11:15 a.m. PDT
Location:The Hilton San Francisco, 333 O’Farrell Street, San Francisco, CA
The Franciscan B Room

About First Wave BioPharma, Inc.
First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple Phase 2 clinical stage programs built around three proprietary technologies – the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency; capeserod, a selective 5-HT4 receptor partial agonist which First Wave will pursue for gastrointestinal (GI) indications; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit www.firstwavebio.com.

For more information:
First Wave BioPharma, Inc.
777 Yamato Road, Suite 502
Boca Raton, FL 33431
Phone: (561) 589-7020
info@firstwavebio.com

Media contact:
Tiberend Strategic Advisors, Inc.
David Schemelia
(609) 468-9325
dschemelia@tiberend.com


FAQ

When is the presentation at the 2023 BIO Investor Forum?

The presentation will take place on October 17, 2023 at 11:15 a.m. PDT.

Where will the presentation be held?

The presentation will be held at the Hilton San Francisco in the Franciscan B Room.

What will be discussed during the presentation?

The presentation will cover First Wave BioPharma's company overview, updates, business and clinical development strategy, recent corporate achievements, and anticipated milestones.

Who will be presenting?

James Sapirstein, Chairman, President, and CEO of First Wave BioPharma, will be presenting.

Will there be one-on-one meetings with investors?

Yes, members of the First Wave BioPharma management team will conduct one-on-one meetings with registered investors at the conference.

First Wave BioPharma, Inc.

NASDAQ:FWBI

FWBI Rankings

FWBI Latest News

FWBI Stock Data

5.99M
2.75M
5.66%
1.46%
2.3%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOCA RATON